Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.83 |
| ▸ | FAAH | O00519 | 1/20 | 0.83 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.83 |
| ▸ | HPGD | P15428 | 1/20 | 0.83 |
| ▸ | CNR1 | P21554 | 1/20 | 0.83 |
| ▸ | CNR2 | P34972 | 1/20 | 0.83 |
| ▸ | PRKCA | P17252 | 3/20 | 0.81 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.81 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.81 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.81 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.81 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.68 |
| ▸ | DGKA | P23743 | 1/20 | 0.62 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.61 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16172 | 1.00 | MAPT (0.83) | MAPTFAAHALDH1A1HPGDCNR1 | |
| SCHEMBL9775032 | 1.00 | MAPT (0.83) | MAPTFAAHALDH1A1HPGDCNR1 | |
| SCHEMBL2710000 | 1.00 | MAPT (0.83) | MAPTFAAHALDH1A1HPGDCNR1 | |
| SCHEMBL18632787 | 1.00 | MAPT (0.83) | MAPTFAAHALDH1A1HPGDCNR1 | |
| SCHEMBL19756819 | 1.00 | MAPT (0.83) | MAPTFAAHALDH1A1HPGDCNR1 | |
| SCHEMBL30454466 | 1.00 | MAPT (0.83) | MAPTFAAHALDH1A1HPGDCNR1 | |
| SCHEMBL30863748 | 1.00 | MAPT (0.83) | MAPTFAAHALDH1A1HPGDCNR1 | |
| SCHEMBL14856360 | 0.98 | MAPT (0.81) | MAPTFAAHALDH1A1HPGDCNR1 | |
| SCHEMBL10709380 | 0.98 | MAPT (0.81) | MAPTFAAHALDH1A1HPGDCNR1 | |
| Ethylene SCHEMBL6976654 | 0.97 | MAPT (0.78) | MAPTFAAHALDH1A1HPGDCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 495 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4308248-B1 | COSMETIC SKIN CARE COMPOSITION | UNILEVER IP HOLDINGS B V (NL) | 2026-05-06 | — | — | EP | claimed |
| EP-4695192-A2 | ANALGESIC COMPOUNDS COMPRISING CHARGED PARTICLES AND METHOD OF MANUFACTURE THEREOF | University of Connecticut (US) | 2026-02-18 | — | — | EP | claimed |
| US-12281070-B2 | Water soluble antiviral and antimicrobial compound and process for preparation thereof | DEB NILANJAN (IN) | 2025-04-22 | — | — | US | claimed |
| WO-2024216279-A2 | ANALGESIC COMPOUNDS COMPRISING CHARGED PARTICLES AND METHOD OF MANUFACTURE THEREOF | UNIVERSITY OF CONNECTICUT (US) | 2024-10-17 | — | — | WO | claimed |
| US-20240261252-A1 | Methods of use and formulations of allosteric modulators of the serotonin, dopamine and other receptor systems for medical, recreational, religious, research and other uses. | HELDRETH JR DAVID ALAN (US) | 2024-08-08 | — | — | US | claimed |
| US-20240173231-A1 | COSMETIC SKIN CARE COMPOSITION | CONOPCO, INC., D/B/A UNILEVER (US) | 2024-05-30 | — | — | US | claimed |
| US-11892458-B2 | Biochemical predictors of red blood cell quality | BLOODWORKS NW (US) | 2024-02-06 | — | — | US | claimed |
| EP-4308248-A1 | COSMETIC SKIN CARE COMPOSITION | Unilever IP Holdings B.V. (NL) | 2024-01-24 | — | — | EP | claimed |
| CN-117177734-A | Cosmetic skin care compositions | 联合利华知识产权控股有限公司 | 2023-12-05 | — | — | CN | claimed |
| US-20230225952-A1 | ADDITIVES FOR COLORING AGENTS AND METHODS OF USE THEREOF | LIVING PROOF, INC. | 2023-07-20 | — | — | US | claimed |
| EP-2445494-A1 | TREATMENT OF INSULIN RESISTANCE AND OBESITY BY STIMULATING GLP-1 RELEASE | Københavns Universitet (DK) | 2012-05-02 | — | — | EP | claimed |
| WO-2010149170-A1 | TREATMENT OF INSULIN RESISTANCE AND OBESITY BY STIMULATING GLP-1 RELEASE | Københavns Universitet (DK) | 2010-12-29 | — | — | WO | claimed |
| EP-1104231-B1 | BIODEGRADABLE HIGH OXIDATIVE STABILITY OILS | CARGILL INC (US) | 2008-11-26 | — | — | EP | claimed |
| WO-2007147023-A1 | AN ASSAY FOR MEASURING ACYLTRANSFERASE ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-21 | — | — | WO | claimed |
| US-20070292906-A1 | ASSAY FOR MEASURING ACYLTRANSFERASE ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2007-12-20 | — | — | US | claimed |
| EP-1104231-A4 | BIODEGRADABLE HIGH OXIDATIVE STABILITY OILS | CARGILL INC (US) | 2004-04-28 | — | — | EP | claimed |
| US-20010037514-A1 | Biodegradable high oxidative stability oils | CARGILL, INCORPORATED, DELAWARE CORPORATION | 2001-11-01 | — | — | US | claimed |
| EP-1104231-A1 | BIODEGRADABLE HIGH OXIDATIVE STABILITY OILS | Cargill, Inc. (US) | 2001-06-06 | — | — | EP | claimed |
| WO-2000007432-A9 | BIODEGRADABLE HIGH OXIDATIVE STABILITY OILS | CARGILL INC (US) | 2000-11-16 | — | — | WO | claimed |
| WO-2000007432-A1 | BIODEGRADABLE HIGH OXIDATIVE STABILITY OILS | CARGILL, INCORPORATED (US) | 2000-02-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240173231-A1 | COSMETIC SKIN CARE COMPOSITION | CUTA, RARA, RBP1 | MAPT 1358/4885FAAH 1456/4885ALDH1A1 613/4885 |
| US-12281070-B2 | Water soluble antiviral and antimicrobial compound and process for preparation thereof | ZC3HAV1, SAMHD1, ZC3HAV1L | MAPT 4004/4885FAAH 3856/4885ALDH1A1 3253/4885 |
| US-20230225952-A1 | ADDITIVES FOR COLORING AGENTS AND METHODS OF USE THEREOF | COXFA4L2, TYR, OAT | MAPT 1993/4885FAAH 3205/4885ALDH1A1 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.